Compare KNOP & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNOP | EOLS |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.1M | 454.4M |
| IPO Year | 2012 | 2018 |
| Metric | KNOP | EOLS |
|---|---|---|
| Price | $11.01 | $6.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 75.1K | ★ 732.1K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $3.51 | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $6.76 | $3.86 |
| 52 Week High | $11.78 | $10.20 |
| Indicator | KNOP | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.84 | 57.46 |
| Support Level | $10.04 | $6.44 |
| Resistance Level | $11.67 | $7.35 |
| Average True Range (ATR) | 0.32 | 0.29 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 88.06 | 60.00 |
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.